Yi Chen1, Jinyu Li2, Yibao Zhang3, Yi Hu2, Guoqing Zhang2, Xiang Yan2, Zhi Lin2, Zhifei Zhao4, Shunchang Jiao5,6. 1. School of Clinical Medicine, Tsinghua University, Beijing, China. 2. Department of Medical Oncology, Chinese PLA General Hospital, Beijing, China. 3. Department of Radiotherapy, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China. 4. Department of Radiation Oncology, Chinese PLA General Hospital, Beijing, China. 5. Department of Medical Oncology, Chinese PLA General Hospital, Beijing, China. jiaosc_301pla@163.com. 6. , 28 Fu Xing Road, Haidian District, 100853, Beijing, China. jiaosc_301pla@163.com.
Abstract
OBJECTIVE: Previous studies demonstrated that prophylactic cranial irradiation (PCI) significantly reduced the incidence of brain metastases in patients with extensive disease small cell lung cancer (ED-SCLC). However, the appropriate timing for PCI in treating ED-SCLC is still unclear. This study aimed to compare the effect and safety of early versus late PCI. METHODS: Between November 2011 and July 2016, 103 patients with ED-SCLC were reviewed, receiving appropriate imaging tests to exclude brain metastases prior to cranial irradiation. Of these 103 patients, early PCI was performed in 47 patients and the other 56 patients received late PCI. The primary endpoint was the incidence of brain metastases. The progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were also assessed. RESULTS: Early PCI significantly lowered the risk of brain metastases, as compared to late PCI (p = 0.024). Additionally, multivariate analyses demonstrated that early PCI was a favorable independent predictor of the incidence of brain metastases. The PFS and OS of patients in the early and late PCI groups were comparable (PFS: 8.4 months vs. 7.5 months, p = 0.234; OS: 16.1 months vs. 15.2 months, p = 0.753). The AEs were generally acceptable in both groups. CONCLUSION: To reduce the incidence of brain metastases, early PCI is more effective than late PCI for ED-SCLC patients.
OBJECTIVE: Previous studies demonstrated that prophylactic cranial irradiation (PCI) significantly reduced the incidence of brain metastases in patients with extensive disease small cell lung cancer (ED-SCLC). However, the appropriate timing for PCI in treating ED-SCLC is still unclear. This study aimed to compare the effect and safety of early versus late PCI. METHODS: Between November 2011 and July 2016, 103 patients with ED-SCLC were reviewed, receiving appropriate imaging tests to exclude brain metastases prior to cranial irradiation. Of these 103 patients, early PCI was performed in 47 patients and the other 56 patients received late PCI. The primary endpoint was the incidence of brain metastases. The progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were also assessed. RESULTS: Early PCI significantly lowered the risk of brain metastases, as compared to late PCI (p = 0.024). Additionally, multivariate analyses demonstrated that early PCI was a favorable independent predictor of the incidence of brain metastases. The PFS and OS of patients in the early and late PCI groups were comparable (PFS: 8.4 months vs. 7.5 months, p = 0.234; OS: 16.1 months vs. 15.2 months, p = 0.753). The AEs were generally acceptable in both groups. CONCLUSION: To reduce the incidence of brain metastases, early PCI is more effective than late PCI for ED-SCLCpatients.
Entities:
Keywords:
Chemotherapy; Dose fractionation; Metastases; Radiotherapy; Small cell lung carcinoma
Authors: Ahsan S Farooqi; Emma B Holliday; Pamela K Allen; Xiong Wei; James D Cox; Ritsuko Komaki Journal: Radiother Oncol Date: 2017-01-07 Impact factor: 6.280
Authors: R Feld; J F Pringle; W K Evans; C W Keen; I C Quirt; J E Curtis; M A Baker; J L Yeoh; G Deboer; T C Brown Journal: Arch Intern Med Date: 1981-03
Authors: Haiyan Zeng; Danyang Zheng; Willem J A Witlox; Antonin Levy; Alberto Traverso; Feng-Ming Spring Kong; Ruud Houben; Dirk K M De Ruysscher; Lizza E L Hendriks Journal: Front Oncol Date: 2022-06-10 Impact factor: 5.738